---
title: "Roth MKM Sticks to Its Buy Rating for Aptevo Therapeutics (APVO)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280818066.md"
description: "Roth MKM analyst Jonathan Aschoff has reaffirmed a Buy rating for Aptevo Therapeutics (APVO) with a price target of $21.00. Despite Aschoff's average return of -20.7% and a 29.05% success rate, the overall analyst consensus for Aptevo is a Moderate Buy, also with a $21.00 average price target."
datetime: "2026-03-27T15:25:14.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280818066.md)
  - [en](https://longbridge.com/en/news/280818066.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280818066.md)
---

# Roth MKM Sticks to Its Buy Rating for Aptevo Therapeutics (APVO)

Roth MKM analyst Jonathan Aschoff maintained a Buy rating on Aptevo Therapeutics today and set a price target of $21.00.

### Claim 30% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

According to TipRanks, Aschoff is an analyst with an average return of \-20.7% and a 29.05% success rate. Aschoff covers the Healthcare sector, focusing on stocks such as Pelthos Therapeutics, Aptevo Therapeutics, and Biofrontera.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Aptevo Therapeutics with a $21.00 average price target.

### Related Stocks

- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [APVO.US](https://longbridge.com/en/quote/APVO.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)

## Related News & Research

- [Aptevo targets solid tumors with planned Nectin-4 x PD-L1 dual-targeting platform strategy](https://longbridge.com/en/news/293969770.md)
- [Medicare is about to change a drug program that held down the cost of premiums. Here's what to know.](https://longbridge.com/en/news/294391519.md)
- [HEDGE FLOW-Hedge fund bets on rising US healthcare stocks near 5-year high, Goldman says](https://longbridge.com/en/news/293938581.md)
- [IT Sector Accounts for Nearly One Third of U.S. Securities Litigation Risk in 1H 2026](https://longbridge.com/en/news/294507902.md)
- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)